<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HAC58DC9480D44627AA7A22904861365F" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 2439 IH: Fair Accountability and Innovative Research Drug Pricing Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-05-16</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 2439</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170516">May 16, 2017</action-date><action-desc><sponsor name-id="S001145">Ms. Schakowsky</sponsor> (for herself, <cosponsor name-id="D000216">Ms. DeLauro</cosponsor>, <cosponsor name-id="D000399">Mr. Doggett</cosponsor>, <cosponsor name-id="C000984">Mr. Cummings</cosponsor>, and <cosponsor name-id="W000800">Mr. Welch</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To require reporting regarding certain drug price increases, and for other purposes.</official-title></form>
	<legis-body id="H6CCC074462A6488686C681C0CD5B8045" style="OLC">
 <section id="HA48DA1CF254540C0BC622BBB3477E47C" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Fair Accountability and Innovative Research Drug Pricing Act of 2017</short-title></quote>.</text> </section><section id="HAD633B96AC3142228E2D2463D9F03406" section-type="subsequent-section"><enum>2.</enum><header>Reporting on justification for drug price increases</header><text display-inline="no-display-inline">Title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/241">42 U.S.C. 241</external-xref> et seq.) is amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H0F678FD104D441D883BA313A4A550480" style="OLC">
				<part id="H0E8B2E0073DC4683AD07FCDD42CD9CDB" style="OLC"><enum>W</enum><header>Drug Price Reporting; Drug Value Fund</header>
					<section id="H016DDA1B1FD24DBCA28F18FF9ED66A4E"><enum>399OO.</enum><header>Reporting on justification for drug price increases</header>
 <subsection id="H4AFBA100F60A4B17B46939ABD6F58E30"><enum>(a)</enum><header>Definitions</header><text>In this section:</text> <paragraph id="HBA75270249CA4137801C9BEEB9E18479"><enum>(1)</enum><header>Manufacturer</header><text>The term <term>manufacturer</term> means the person—</text>
 <subparagraph id="H0399D6977CD14BF4897EA977FC415CB3"><enum>(A)</enum><text>that holds the application for a drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act or the license issued under section 351 of the Public Health Service Act; or</text>
 </subparagraph><subparagraph id="H25D75851881C4E0C994CF0E8451058CC"><enum>(B)</enum><text>who is responsible for setting the price for the drug.</text> </subparagraph></paragraph><paragraph id="H4F7922E688744C3CB47215B6A0FFB310"><enum>(2)</enum><header>Qualifying drug</header><text>The term <term>qualifying drug</term> means any drug that is approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under subsection (a) or (k) of section 351 of this Act—</text>
 <subparagraph id="H08A8DB9CCBF740A6AB98CA473B924E36"><enum>(A)</enum><text display-inline="yes-display-inline">that has a wholesale acquisition cost of $100 or more per month supply or per a course of treatment that lasts less than a month and is—</text>
									<clause id="HD55433152E864A8E9555EA0F9347FBC6"><enum>(i)</enum>
 <subclause commented="no" display-inline="yes-display-inline" id="HDFB2AEBCD6EA4BE5B9037283825CD277"><enum>(I)</enum><text>subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act; or</text> </subclause><subclause id="H9CB78933AD1044C6944950F6192B10A9" indent="up1"><enum>(II)</enum><text>commonly administered by hospitals (as determined by the Secretary);</text>
 </subclause></clause><clause id="HFCB5163496DD4A6EA8F8805F0FC30667"><enum>(ii)</enum><text>not designated as a drug for a rare disease or condition under section 526 of the Federal Food, Drug, and Cosmetic Act; and</text>
 </clause><clause id="HC60C05FB0DF94BD0B22C2F3693F4E341"><enum>(iii)</enum><text>not designated by the Secretary as a vaccine; and</text> </clause></subparagraph><subparagraph id="HC6E1F4B10C524BF3A4563A829BE49BEB"><enum>(B)</enum><text>for which, during the previous calendar year, at least 1 dollar of the total amount of sales were for individuals enrolled under the Medicare program under title XVIII of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395">42 U.S.C. 1395</external-xref> et seq.) or under a State Medicaid plan under title XIX of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396">42 U.S.C. 1396</external-xref> et seq.) or under a waiver of such plan.</text>
 </subparagraph></paragraph><paragraph id="HA3178C7AFA79401B9C083E467B88205B"><enum>(3)</enum><header>Wholesale acquisition cost</header><text>The term <quote>wholesale acquisition cost</quote> has the meaning given that term in section 1847A(c)(6)(B) of the Social Security Act (42 U.S.C. 1395w–3a(c)(6)(B)).</text>
							</paragraph></subsection><subsection id="H00B13CD2126B48C2A8EB21659ED7FD5B"><enum>(b)</enum><header>Report</header>
 <paragraph id="H37888731BD574F95AF12CF94E3B53E85"><enum>(1)</enum><header>Report required</header><text>The manufacturer of a qualifying drug shall submit a report to the Secretary for each price increase of a qualifying drug that will result in an increase in the wholesale acquisition cost of that drug that is equal to—</text>
 <subparagraph id="HDECDCD8ACFD34D31AE8A3F73D16CCD68"><enum>(A)</enum><text>10 percent or more over a 12-month period; or</text> </subparagraph><subparagraph id="HBE8E51B11B594569808A467156610F51"><enum>(B)</enum><text>25 percent or more over a 36-month period.</text>
 </subparagraph></paragraph><paragraph id="HFE09620B940747B8992FDCD443381630"><enum>(2)</enum><header>Report deadline</header><text>Each report described in paragraph (1) shall be submitted to the Secretary not later than 30 days prior to the planned effective date of such price increase.</text>
 </paragraph></subsection><subsection id="H18C9FE26AC1642EEBF1AE5EE6FF36D37"><enum>(c)</enum><header>Contents</header><text>A report under subsection (b) shall, at a minimum, include—</text> <paragraph id="HAAD7A629DA16432DBCE32226081A5FDE"><enum>(1)</enum><text>with respect to the qualifying drug—</text>
 <subparagraph id="H496E6EBD282F4B6E86006CACFF6C2ACE"><enum>(A)</enum><text>the percentage by which the manufacturer will raise the wholesale acquisition cost of the drug on the planned effective date of such price increase;</text>
 </subparagraph><subparagraph id="H489E1CAF265A42C2AE0A5C9B01739DB2"><enum>(B)</enum><text>a justification for, and description of, each manufacturer’s price increase that occurred during the 12-month period described in subsection (b)(1)(A) or the 36-month period described in subsection (b)(1)(B), as applicable;</text>
 </subparagraph><subparagraph id="H6F34447092ED4254B419D109035143D7"><enum>(C)</enum><text>the identity of the initial developer of the drug;</text> </subparagraph><subparagraph id="H7850B8EF30A641DB936767A2F6B26659"><enum>(D)</enum><text>a description of the history of the manufacturer's price increases for the drug since the approval of the application for the drug under section 505 of the Federal Food, Drug, and Cosmetic Act or the issuance of the license for the drug under section 351, or since the manufacturer acquired such approved application or license;</text>
 </subparagraph><subparagraph id="H43F7150C6D0C425B8E36F17F1DB573D1"><enum>(E)</enum><text>the current list price of the drug;</text> </subparagraph><subparagraph commented="no" id="H60C52CD9EF404BE7994C62BE4ADA5C6B"><enum>(F)</enum><text>the total expenditures of the manufacturer on—</text>
 <clause commented="no" id="HDD55EA2F3DDF493CBFAE88FF714BF425"><enum>(i)</enum><text>materials and manufacturing for such drug; and</text> </clause><clause commented="no" id="H4496B8969243477BBCFA24C7CBA7A4F5"><enum>(ii)</enum><text>acquiring patents and licensing for such drug;</text>
 </clause></subparagraph><subparagraph id="HE17029E1BC0F4259A8F5A6CD4F072261"><enum>(G)</enum><text>the percentage of total expenditures of the manufacturer on research and development for such drug that was derived from Federal funds;</text>
 </subparagraph><subparagraph id="H37357747931A4A4FA707991D99919457"><enum>(H)</enum><text>the total expenditures of the manufacturer on research and development for such drug that is used for—</text>
 <clause id="HE5BCA2EFB7B64F11B68775D3EB5F18E0"><enum>(i)</enum><text>basic and preclinical research;</text> </clause><clause id="HA0AA0A951BA946E189294F4479143943"><enum>(ii)</enum><text>clinical research;</text>
 </clause><clause id="HAA1F0C5C0A5547F3948A4C6715DE429C"><enum>(iii)</enum><text>new drug development;</text> </clause><clause id="H99B29B7CC48B439F9C771E71F8E78F36"><enum>(iv)</enum><text>pursuing new or expanded indications for such drug through supplemental applications under section 505 of the Federal Food, Drug, and Cosmetic Act; and</text>
 </clause><clause id="H9B91F0611F7A4854B55329F51258F571"><enum>(v)</enum><text>carrying out postmarket requirements related to such drug, including those under section 505(o)(3) of such Act;</text>
 </clause></subparagraph><subparagraph id="H4AA791583971442B8FABB8491995D374"><enum>(I)</enum><text>the total revenue and the net profit generated from the qualifying drug for each calendar year since the approval of the application for the drug under section 505 of the Federal Food, Drug, and Cosmetic Act or the issuance of the license for the drug under section 351, or since the manufacturer acquired such approved application or license; and</text>
 </subparagraph><subparagraph id="H07C4B0E1077742F980F08DAFB701FD00"><enum>(J)</enum><text>the total costs associated with marketing and advertising for the qualifying drug;</text> </subparagraph></paragraph><paragraph id="H8644C269B2B249B19ECFF812964784EA"><enum>(2)</enum><text>with respect to the manufacturer—</text>
 <subparagraph id="H51D772F4C1CB4E108AC14A1EF1C02F5C"><enum>(A)</enum><text>the total revenue and the net profit of the manufacturer for the 12-month period described in subsection (b)(1)(A) or the 36-month period described in subsection (b)(1)(B), as applicable;</text>
 </subparagraph><subparagraph id="HC58F514600E142CA9C8902D4B9DC28B0"><enum>(B)</enum><text display-inline="yes-display-inline">all stock-based performance metrics used by the manufacturer to determine executive compensation for the 12-month period described in subsection (b)(1)(A) or the 36-month period described in subsection (b)(1)(B), as applicable; and</text>
 </subparagraph><subparagraph id="HACC558442AA94433A2B25831C2989922"><enum>(C)</enum><text>any additional information the manufacturer chooses to provide related to drug pricing decisions, such as total expenditures on—</text>
 <clause id="H7B785201CA0F476097B01A1DDB95EE51"><enum>(i)</enum><text>drug research and development; or</text> </clause><clause id="HE8E033E9EE624557916B56B65175EA18"><enum>(ii)</enum><text>clinical trials on drugs that failed to receive approval by the Food and Drug Administration; and</text>
 </clause></subparagraph></paragraph><paragraph id="HB88B48F7822D436593CDA7D59B26F129"><enum>(3)</enum><text>such other related information as the Secretary considers appropriate.</text> </paragraph></subsection><subsection id="HAAA22655714144EAB37FDBA2330DE59F"><enum>(d)</enum><header>Civil penalty</header><text>Any manufacturer of a qualifying drug that fails to submit a report for the drug as required by this section shall be subject to a civil penalty of $100,000 for each day on which the violation continues.</text>
						</subsection><subsection id="H80412C3E156E4A4FB877C7D688F5C595"><enum>(e)</enum><header>Public posting</header>
 <paragraph id="HF335636F20C2488DB4022FCBA3C67FAE"><enum>(1)</enum><header>In general</header><text>Subject to paragraph (3), not later than 30 days after the submission of a report under subsection (b), the Secretary shall post the report on the public website of the Department of Health and Human Services.</text>
 </paragraph><paragraph id="H1A8DA2A35564475CA9011233E441D147"><enum>(2)</enum><header>Format</header><text>In developing the format of such report for public posting, the Secretary shall consult stakeholders, including beneficiary groups, and shall seek feedback on the content and format from consumer advocates and readability experts to ensure such public reports are user-friendly to the public and are written in plain language that consumers can readily understand.</text>
 </paragraph><paragraph commented="no" id="HD5416C0C02F4416E9297F64725DE9D79"><enum>(3)</enum><header>Trade secrets and confidential information</header><text display-inline="yes-display-inline">In carrying out this section, the Secretary shall enforce applicable law concerning the protection of confidential commercial information and trade secrets.</text></paragraph></subsection></section></part><after-quoted-block>.</after-quoted-block></quoted-block>
			<quoted-block display-inline="no-display-inline" id="HA73B036BA85F44B894754EA3F6BDE67D" style="OLC">
 <section id="H6299E3144C2B40968CB0712CB6203F49"><enum>399OO–1.</enum><header>Use of civil penalty amounts</header><text display-inline="no-display-inline">The Secretary shall collect the civil penalties under section 399OO, in addition to any other amounts available, and without further appropriation, and shall use such funds to carry out activities described in this part and to improve consumer and provider information about drug value and drug price transparency.</text>
				</section><section id="H5ADC2CBBC7494D2CBBC88AED85576637"><enum>399OO–2.</enum><header>Annual report to Congress</header>
 <subsection id="HC43526BEEDE94A85B1DDD43177B1BF2A"><enum>(a)</enum><header>In General</header><text display-inline="yes-display-inline">Subject to subsection (b), the Secretary shall submit to Congress, and post on the public website of the Department of Health and Human Services in a way that is easy to use and understand, an annual report—</text>
 <paragraph id="H83F12CE93B9C45EF8144DCDB890B4115"><enum>(1)</enum><text display-inline="yes-display-inline">summarizing the information reported pursuant to section 399OO; and</text> </paragraph><paragraph id="H611F99A0BBCF4E12AA06BAD902E4D6F5"><enum>(2)</enum><text display-inline="yes-display-inline">including copies of the reports and supporting detailed economic analyses submitted pursuant to such section.</text>
 </paragraph></subsection><subsection id="HC0E4AEB3DD234ED088780EF8895B9638"><enum>(b)</enum><header>Trade secrets and confidential information</header><text display-inline="yes-display-inline">In carrying out this section, the Secretary shall enforce applicable law concerning the protection of confidential commercial information and trade secrets.</text>
					</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body></bill>


